RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.

@article{Nishio2010RUNX3PM,
  title={RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.},
  author={Minoru Nishio and Chouhei Sakakura and Tomoyuki Nagata and Sosuke Komiyama and A. Miyashita and Takuo Hamada and Yoshiaki Kuryu and Hisashi Ikoma and Takeshi Kubota and Akio Kimura and Masayoshi Nakanishi and Daisuke Ichikawa and Hitoshi Fujiwara and Kazuma Okamoto and Toshiya Ochiai and Yukihito Kokuba and Teruhisa Sonoyama and Hiroshia Ida and Kosei Ito and Tsutomu Chiba and Yoshiaki Ito and Eigo Otsuji},
  journal={Anticancer research},
  year={2010},
  volume={30 7},
  pages={2673-82}
}
BACKGROUND/AIM RUNX3 is a novel gastric cancer tumor suppressor. RUNX3 promoter hypermethylation is associated with many types of cancer, including colorectal cancer. Furthermore, the RUNX3 promotor is one of the CpG island methylator phenotype (CIMP)-specific promotors. CIMP is a distinct phenotype associated with microsatellite instability (MSI) in colorectal cancer. In this study, the suitability of the quantitative analysis of RUNX3 promoter hypermethylation as a novel serum tumor marker… CONTINUE READING